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Abstract: In July 2008, the Western Australia (WA) Department of Health embarked on a landmark 5-year project to 
implement a sustainable comprehensive health-system-wide Patient Blood Management Program. Fundamentally, it was a 
quality and safety initiative, which also had profound resource and economic implications. Unsustainable escalating direct 
and indirect costs of blood, potentially severe blood shortages due to changing population dynamics, donor deferrals, loss 
of altruism, wide variations in transfusion practice and growing knowledge of transfusion limitations and adverse 
outcomes necessitate a paradigm shift in the management of anemia and blood loss. The concept of patient-focused blood 
management is proving to be an effective force for change. This approach has now evolved to embrace comprehensive 
hospital-wide Patient Blood Management Programs. These programs show significant reductions in blood utilisation, 
reduced costs while achieving similar or improved patient outcomes. The WA Program is achieving these outcomes 
across a health jurisdiction in a sustained manner.  
Keywords: Anemia, blood conservation, blood loss, blood transfusion, patient blood management, bloodless surgery, practice 
change. 
INTRODUCTION 
 Patient blood management (PBM) shifts the attention in 
transfusion medicine from a product focus to a patient focus 
and managing the patient’s own blood [1]. PBM is an 
evidence-based, patient-specific medical and surgical 
concept that employs a multidisciplinary multimodal team 
approach to optimise the patient’s red cell mass, minimise 
blood loss and exploit and optimise the patient’s 
physiological tolerance of anemia. Its aim is to improve 
patient outcomes [2-4]. There is now worldwide interest and 
uptake in PBM [5]. In May 2010, the sixty-third session of 
the decision-making body of the World Health Organisation, 
the World Health Assembly (WHA), adopted resolution 
WHA63.12 which recommended PBM to its 193 member 
states [6]. In 2008, the Australian National Blood Authority 
(NBA) commenced the development of 6 evidence-based  
 
*Address correspondence to this author at the School of Surgery, Faculty of 
Medicine, Dentistry and Health Sciences, The University of Western 
Australia; E-mail: shannon.farmer@uwa.edu.au 
Patient Blood Management Guidelines modules covering 1) 
Critical Bleeding/Massive Transfusion, 2) Perioperative, 3) 
Medical, 4) Critical Care, 5) Obstetrics and Maternity and 6) 
Paediatrics and Neonatology. PBM is most effective when 
implemented as part of a coordinated program [7-9]. Based 
on an exhaustive review of the literature the NBA Patient 
Blood Management Guidelines: Module 2 Perioperative 
contains an evidence-based recommendation that “Health-
care services should establish a multidisciplinary, 
multimodal perioperative patient blood management 
program”[10]. Numerous reports in the literature show that 
these programs are achieving change, resulting in significant 
reductions in blood utilisation while improving patient 
outcomes and reducing costs (see Fig. 1)[9, 11-30]. In 2014 
the Consumers, Health and Food Executive Agency of the 
European Union (EU) Commission undertook a project to 
develop an “EU Guide for Member States on Good Practices 
for Patient Blood Management”, acknowledging the patient 
outcome and cost saving benefits of PBM (http://www. 
newsfox.com/news/20140321006). A provisional blood 
conservation program in Ontario Canada in 2002 was the 
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first government-sponsored jurisdictional program [31]. It 
focused on three targeted surgical procedures namely, knee 
replacement surgery, aortic aneurysm surgery and elective 
coronary artery bypass surgery. The WA PBM Program was 
the world’s first proposed comprehensive jurisdiction-wide 
program encompassing all medical and surgical specialties 
[32]. We outline here the rationale for the WA Program, its 
implementation and preliminary results. These outcomes 
have implications for both the developed and developing 
world. 
RATIONALE 
The Pressing Need for Change in Transfusion Practice 
 In 1988, Isbister highlighted the need for a paradigm 
change in transfusion practice [33, 34]. An editorial in 
the British Medical Journal in 2002 stated that change 
would require a “cultural shift” at all levels of the health 
system including clinicians, managers and policy makers. 
Changing culture in transfusion practice, however, has 
been challenging [35]. Boucher and Hannon noted this in 
a 2007 paper writing that the “administration of blood 
products is surrounded by emotions, misconceptions, 
myths, and prescribing by habits” [36]. Dzik of the 
Massachusetts General Hospital Blood Transfusion 
Service in his 2002 Emily Cooley lecture published in the 
journal Transfusion highlighted a need for change and 
referred to “a verbal tradition of blood usage in which old 
‘rules’, often perilously out of date, are used to decide 
when to transfuse” and “that many transfusion decisions 
are ill informed, outdated, or simply incorrect” [34]. New 
reasons for change have emerged in recent years, 
meaning the need for change is now more pressing than 
ever. Factors necessitating change include:  
Burgeoning Cost of Blood 
 Economic modelling of transfusion presents a number of 
challenges and is generally poorly understood [37]. 
Traditionally, costing of blood has focused on direct 
acquisition costs – in itself a difficult cost assessment. 
Direct cost of the product, however, represents only a 
fraction of the total cost. Process cost analysis has been 
applied to estimate the total societal cost of blood [38, 
39]. This broad costing needs to take into account not just 
the collecting, screening, testing and processing of blood 
products, but also the process of testing and 
administering blood products within the hospital and the 
associated costs of monitoring and treating adverse 
events of transfusion. A study conducted in two United 
States hospitals and two European hospitals using 
activity-based costing showed that the cost of 
administering red blood cell (RBC) transfusions within 
the hospital was two to four times that of the direct 
costs.[40] On top of the direct cost of blood and the 
activity-based cost of administering transfusions is the 
potential cost of adverse outcomes associated with 
transfusion. In a study of 89,996 multi-day acute-care 
inpatients discharged over a one year period Trentino et 
al. found that, after risk adjustment, the hospital costs 
associated with RBC transfusions represented 7.8% of 
the total hospital expenditure on that patient population. 
 
Fig. (1). Outcomes reported with comprehensive Blood Conservation/Patient Blood Management Programs. Reductions vary 
according to baseline utilization/practice, measure used and level of program implementation. Data compiled from: Frank 2014; Pattakos 
2012; Lapar 2013; Kotze 2012; Moskowitz 2010; Reddy 2009; Brevig 2009; Ferraris 2007; Wong 2007; Ghiglione 2007; Freedman 2008; 
Martinez 2007; DeAnda 2006; Freedman 2005; Pierson 2004; Green 2004; Kourtzis 2004; Morgan 2004; Slappendel 2003; Van der Linden 
2001; Helm 1998. 
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This costing does not include the cost of the blood 
products [41]. Accordingly, the total cost burden is 
becoming increasingly unsustainable.  
Blood Supply Challenges  
 An additional challenge exists in current population 
dynamics. In many countries a looming socio-economic 
challenge relates to the so-called age-dependency ratio, a 
measure obtained by dividing the non-working-age 
population by the working-age population and multi-
plying by 100. For example, data from 25 EU countries 
showed an age dependency ratio of 24.8 in 2005, which 
meant that on average 24.8 elderly persons were 
depending on the economic activities of 100 working 
individuals. Based on current population data it is 
estimated that this load may climb over the next 20 years 
to almost 40 [42]. Hofmann et al showed how the “age-
dependency-ratio” can be translated to a “total 
transfusion dependency ratio” (TTDR) to measure the 
changing ratio between the donating and the non-
donating population segments [37]. Studies have shown 
that the majority of blood is used in the older age 
segment of the population – a non-donating blood 
segment (many countries have age limits for donors with 
varying older age and lower age limit cutoffs) [43, 44]. In 
many countries, the donating age group is growing less 
than the rapidly growing older age segment. Farmer et al 
modelled the TTDR for 11 countries to demonstrate the 
potential impact of an ageing population on blood 
supply.[32] In 2010, the TTDR for these 11 selected 
countries ranged from between approximately 31% to 
just under 45%. The modelling estimated that by 2050 
this could increase to between 40% and 65%. This model 
demonstrates the supply challenge if current donation 
patterns remain the same and transfusion practice 
remains unchanged.  
Safety Issues 
 Although the risk of known infectious agents such as 
human immunodeficiency virus (HIV), hepatitis C virus 
(HCV) and hepatitis B virus (HBV) has been reduced to 
very low levels in most developed countries, the blood 
supply remains vulnerable to new and re-emerging 
infectious agents.[45, 46] Highlighting this challenge, in 
the proceedings of a US Food and Drug Administration 
(FDA) public workshop on the risk of emerging 
infectious diseases (EID) for blood and blood products 
published in 2013, one of the participants, Dr Susan 
Stramer from the American Red Cross, is reported as 
stating: “EID agents are unique with few common 
characteristics. Their emergence is unpredictable, 
generalization about them is dangerous, vigilance is 
critical, and one solution does not fit all situations.”[47] 
Additionally, transfusion-related circulatory overload 
(TACO), transfusion-related acute lung injury (TRALI), 
wrong blood component transfused, acute transfusion 
reactions and bacterial contamination of blood remain the 
leading causes of transfusion-related death and major 
morbidity.[48]  
Patient Outcome Issues 
 While blood transfusion is potentially life-saving in the 
setting of critical bleeding and bone marrow failure, 
reviews of the literature demonstrate evidence to support 
benefit for transfusion in the majority of clinical settings 
in which it is given is sparse.[49-51] Recent systematic 
Table 1. Adverse outcomes reported to be associated with red blood cell transfusion. 
Infection Pulmonary complications 
Bacteremia  Neurological complications 
Sepsis/septic shock Venous thromboembolism 
Transfusion-related acute lung injury  Arterial thromboembolism 
Multisystem organ failure Diminished postoperative functional recovery 
Acute respiratory distress syndrome Decreased in-hospital muscle strength 
Prolonged mechanical ventilation Bleeding requiring reoperation 
Vasospasm Increased admission to ICU 
Low-output heart failure Increased ICU length of stay 
Atrial fibrillation Increased hospital length of stay 
Myocardial infarction Increased hospital readmission 
Cardiac arrest Reduced rate of patients discharged to home 
Acute coronary syndrome Cancer recurrence 
Stroke Development of Non-Hodgkin lymphoma 
Renal impairment/failure Increased mortality 
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reviews and meta-analyses of randomized controlled 
trials that compare hemoglobin (Hb) based liberal 
transfusion thresholds with restrictive transfusion 
thresholds establish no benefit from liberal transfusion. 
These meta-analyses, however, have identified possible 
harm from liberal transfusion. A 2012 review found 
liberal transfusion thresholds increased infection and in-
hospital mortality.[52] A 2014 review and meta-analysis 
found that when compared with more restrictive 
transfusion thresholds, liberal transfusion increased the 
incidence of acute coronary syndrome, pulmonary 
edema, re-bleeding, bacterial infection, in-hospital 
mortality, 30-day mortality, and total mortality.[53]  
 The International Consensus Conference on Transfusion 
Outcomes (ICCTO) was convened to try to determine 
from the literature when RBC transfusion may be 
beneficial in improving patient outcomes, when it is not 
beneficial and when it may be harmful.[54] A systematic 
review of the literature published over 13 years identified 
494 studies for analysis. The 15-member panel of 
international experts used the RAND/UCLA 
Appropriateness Method to determine the 
appropriateness (defined as likely to improve the patients 
health outcome) of RBC transfusion in 450 clinical 
scenarios in which transfusion is most commonly 
considered. The analysis was confined to non-actively 
bleeding patients to avoid the confounding of critical 
bleeding. Based on the literature, the expert panel 
concluded that in only 11.8% of the 450 clinical 
scenarios was transfusion likely to improve patient health 
outcomes. In 59.3% of the scenarios transfusion was 
determined to not likely improve health outcomes, even 
likely to harm. In 28.9% of the scenarios, it was found to 
be uncertain whether transfusion would be beneficial, 
with more research required to make definitive 
conclusions. 
 Of greater concern is a growing body of large phase 4 
retrospective and prospective clinical observational 
studies comparing transfused patients with non-
transfused patients after controlling for confounding 
variables showing transfusion per se to be an independent 
risk factor for adverse patient outcomes (see Table 1 for a 
list of adverse outcomes associated with transfusion).[49] 
While there are inherent limitations with observational 
studies, these large real world trials play an important 
role in identifying safety issues – issues that RCTs are 
often too small to pick up.[55, 56]  
 An exhaustive systematic review of the literature was 
conducted for the development of the Australian Patient 
Blood Management Guidelines: Module 2 Perioperative 
to answer the clinical question: “In patients undergoing 
surgery, what is the effect of RBC transfusion on patient 
outcomes?”[10] This review found that in cardiac and 
non-cardiac surgery, RBC transfusion is independently 
associated with increased morbidity, intensive care unit 
(ICU) and hospital length of stay and mortality. Many of 
these studies showed a dose-response relationship, with 
the risks increasing with each unit given.  
 Recent studies have identified that even small amounts of 
transfusion (1 or 2 units) may have a negative impact on 
patient health outcomes, with an associated increased risk 
of mortality, wound problems, pulmonary complications, 
pneumonia, sepsis/septic shock, stroke, renal 
dysfunction/failure, atrial fibrillation, prolonged 
ventilation, re-operation for bleeding, ICU and hospital 
length of stay.[57-60]  
 Mechanisms suggested to explain the adverse outcomes 
associated with transfusion include the physical and 
chemical changes that take place with removal and 
storage of blood (referred to as the “storage lesion”) and 
transfusion-related immunomodulation (TRIM).[61-67] 
The link between TRIM and postoperative infection is 
considered causal and the link between TRIM and cancer 
recurrence is considered likely. [67]  
 If the link between transfusion and adverse outcomes is 
causal, adverse outcomes may represent the largest 
clinical and economic burden of inappropriate 
transfusion.[56] Accordingly, for these and other reasons, 
authorities are now recommending that efforts should be 
directed at minimising or avoiding transfusions wherever 
possible.[9]  
Variations in Transfusion Practice and Inappropriate 
Transfusions 
 Adverse outcomes associated with transfusion are of 
particular concern, given the wide variations in 
transfusion practice that exist between countries and 
institutions.[68-73] Red blood cell transfusion rates vary 
from 9% to 92% in orthopedic surgery, 17% to 82% in 
colorectal surgery, 20% to 53% in critical care and 0% to 
28% in acute coronary syndrome.[74-78] Frank et al 
found wide variation in transfusion practice even 
between clinicians within the same institution.[79] This 
wide variation in transfusion practice in similar patient 
populations suggests that a large percentage of 
transfusions may be inappropriate and avoidable. An 
inappropriate transfusion offers no benefit – only risk to 
the patient and cost to the community.  
Mechanism for Change – Hospital-Wide Comprehensive 
Patient Blood Management Programs 
 The international experience suggests that one of the 
most effective ways to bring about change in practice 
involves establishing formal, comprehensive, hospital-
wide Blood Conservation/PBM programs.[7, 8, 80] 
These coordinated programs adopt aggressive education 
strategies enabling all stakeholders - including patients 
and all clinical and non-clinical hospital staff - to be fully 
informed of current evidence on the risks and benefits of 
transfusion along with measures to minimise blood loss 
and utilise appropriate blood management options. They 
implement an integrated multidisciplinary, multimodal 
medical/surgical approach that has as its focus 
individualised patient care that includes careful 
stewardship of the patient’s own blood. The aim of this 
approach is to improve patient outcomes.[1] As an 
editorial by Frenzel and colleagues in Current Opinion in 
Anaesthesiology put it “Our own blood is still the best 
thing to have in our veins.”[81]  
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 Essential to a successful, comprehensive, PBM program 
is a committed hospital administration, personnel to 
coordinate and manage the program, and a full team of 
well informed and motivated physicians, nurses, 
technicians and other support staff. A hospital-wide 
program conjoins all departments and staff including 
departments of surgery, anesthesia, hematology, critical 
care and pharmacy, along with the pathology laboratory, 
transfusion service and the blood bank. A formal 
program structure is essential to facilitate this 
multidisciplinary team approach.[7, 82] 
 A Patient Blood Management Program identifies patients 
at risk of transfusion and constructs a treatment plan 
aimed at minimising or eliminating such exposure. The 
program provides education for patients to enable them 
to understand their blood management treatment options 
and decisions, improving their satisfaction and comfort 
with the treatment process. A multidisciplinary team 
draws on multiple strategies to minimise blood loss, 
maximise hemopoiesis and manage oxygen needs of the 
individual patient. A “culture” is created, from 
administration through senior and junior clinical staff, 
nursing and allied health, in which allogeneic transfusion, 
like any other tissue transplant, is the last resort, not the 
first reflexive action.  
 PBM is built around three pillars:[32, 83] 
1. Optimise the patient’s red cell mass  
2. Minimise blood loss 
3. Exploit and optimise the tolerance of anemia 
 These three pillars are applied in three integrated phases: 
1) the pre-treatment phase, 2) the treatment phase, and 3) 
the post-treatment phase. 
 Much has been written in the literature and in textbooks 
about this integrated approach and a detailed description 
is beyond the scope of this article.[7, 8, 80, 84-86]  
IMPLEMENTATION OF THE WA PBM PROGRAM 
 The WA PBM Program drew on the accumulated 
international experience in PBM and PBM programs to 
implement for the first time a comprehensive state-wide 
program. It was based on established and proven models[8] 
including a successful Blood Conservation Program 
established by one of the authors (SF) at a WA private 
hospital in 1990.[7] The Program’s aim was to improve 
patient outcomes while reducing costs. The initial 
 
Fig. (2). The 3-pillar 9-field matrix of perioperative patient blood management. The matrix was designed for the Western Australia 
Patient Blood Management Program to assist in the clinical implementation of the multiple PBM strategies. These strategies are considered 
in the perioperative period in a patient/procedure specific context. Adapted from Hofmann A, Friedman D, Farmer S. Western Australian 
Patient Blood Management Project 2008–2012: analysis, strategy, implementation and financial projections. Western Australia Department 
of Health 2007; 1–154. Isbister has adapted this perioperative matrix for wider clinical application, for example medical/haematological 
patient populations (Isbister J. The three-pillar matrix of patient blood management. ISBT Science Series 2015;10(Suppl. 1):286-94). 
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implementation was a five-year project designed to produce 
a sustainable program. It was implemented utilising 
professional change management principles.[87] Effective 
leadership was provided in the Program design with 
Executive sponsorship by the Chief Medical Officer of the 
time, Dr Simon Towler. Clinical leadership also included a 
State PBM Medical Director and a State PBM Nurse 
Coordinator along with a PBM Medical Director and a PBM 
Nurse Coordinator within each major hospital and servicing 
each Area Health Service. The Patient Blood Management 
Guidelines: Module 2 Perioperative (Page 71) highlights the 
major role anesthesiologists play in a PBM Program. 
Anesthesiologists played a key role in the Program with 3 
tertiary-care hospitals appointing them as medical co-
directors. The program also engaged key opinion leaders 
from multiple disciplines as a Clinical Reference Group. 
Multiple education and communication strategies for both 
healthcare providers and consumers were developed, 
including an informative website (http://www.health.wa. 
gov.au/bloodmanagement/home/). Clinical education and 
perioperative clinical practice implementation was structured 
around a 3-pillar 9-field matrix of the multiple perioperative 
PBM strategies (see Fig. 2). Surgical hemostasis workshops 
were developed and run at the State’s Clinical Training and 
Evaluation Centre (CTEC - http://www.ctec.uwa.edu.au) 
during the early part of the program to address the second 
pillar of PBM namely, reducing blood loss. PBM educational 
road shows were conducted at all major hospital departments 
to inform and engage physicians at the clinical coal face. 
Effective data collection and monitoring systems were 
developed for benchmarking, continuous practice improve-
ment and risk management.[88] Systems were re-engineered 
to allow timely optimisation of patient’s hemoglobin and 
iron stores and bleeding risk assessment prior to treatment. 
Details of program structure and implementation are 
discussed in more detail elsewhere.[32, 89] 
RESULTS FROM THE WA PBM PROGRAM 
 The WA PBM Program was announced in November 
2008 in the State that had one of the lowest transfusion rates 
in the developed world.[32] However, issuance had been 
steadily increasing due in part to a rapidly growing 
population. Early reports showed that, with the introduction 
of the program, this upward trend was arrested and trended 
downwards.[32, 89] Four years into the program total RBC 
issuance to the State had decreased from 70,143 units to 
65,742. Historical data, projected age distribution and 
population increases had predicted RBC issuance would 
have reached about 78,000 units by 2012. RBC issuance to 
the 19 capital city hospitals, of which the five major tertiary 
care hospitals were the main preliminary focus of the 
Program, decreased from 38,525 to 34,282 despite a 22.9% 
increase in case-mix-adjusted inpatient activity or weighted 
separations.[32] In the final year of the project (2012-13) 
total issuance for the State was down to 64,064 and issuance 
for 2013-14 was 54,763. This yearly decrease was despite an 
average annual population increase of approximately 3% 
(see Fig. 3)  
 Transfusion services measure blood utilisation of 
countries and jurisdictions in units transfused per 1000 
population. Data available at the commencement of the WA 
 
Fig. (3). Red blood cell issues data and resident population data for the State of Western Australia 2002-03 to 2013-14. Red blood cell 
issuance data published and unpublished National Blood Authority (Australia) data printed with permission. Issuance of red blood cells was 
progressively increasing in Western Australia. With the introduction of the Patient Blood Management Program in 2008-09 this upward trend 
was arrested and issuance has decreased each year despite an annual population increase. 
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Program showed RBC transfusion rates for Denmark, 
Germany, Austria, United States and the United Kingdom as 
being 60.0, 57.3, 52.9, 48.0 and 36.3 respectively. RBC 
issuance for Western Australia was 31.8/1000 (year 2008-
09). This had decreased each year to 25.8/1000 by the end of 
the 5-year project. This decrease has been sustained with 
issuance reaching 21.5/1000 for the year 2013-14 (see Fig. 
4). Reductions have also been seen in fresh frozen plasma 
(FFP) issuance while cryoprecipitate issuance increased. 
This may partly be explained by practice change from using 
FFP to fibrinogen-containing cryoprecipitate in bleeding 
patients. Platelet issuance has remained about the same (see 
Fig. 5.) 
 Initial data presented by one of the main teaching 
hospitals highlights outcomes associated with 
implementation. These data focused on one of the early 
patient groups targeted post program introduction: knee 
replacement (diagnostic related group I04). The data showed 
a significant reduction in the proportion of patients 
transfused from 10.5% pre PBM implementation to 2.2% 
post implementation (p<0.001). In addition to reducing the 
transfusion rate, the data suggests evidence of improved 
patient outcomes. Reduction in unadjusted mean hospital 
length of stay fell from 8.74 days to 7.58 days (p=0.002). 
Using Classification of Hospital Acquired Diagnoses data 
[90] four key areas of hospital-acquired complications were 
identified: hospital-acquired anemia, post-procedural 
complications, cardiovascular complications and respiratory 
complications. The composite incidence of these 
complications was significantly reduced from 15.3% to 
10.2% post PBM implementation (p=0.031). Analysed 
individually this was made up of reductions in the incidence 
of post-procedural complications from 6.7% to 3.1% 
(p=0.021) and small (non-statistically significant) reductions 
in cardiovascular and respiratory complications (5.4% vs 
5.2%; p=0.905 and 2.8% vs. 2.5%; p=0.763 
respectively).[91]  
 While the literature demonstrates an association between 
RBC transfusion and increased length of stay and hospital 
acquired complications, a reduction in transfusion from 
10.5% to 2.2% cannot fully explain the improved outcomes 
seen in this cohort study. Likely, contributing to these is the 
improved care of the PBM approach namely, careful patient 
evaluation and optimisation prior to surgery, meticulous 
surgical technique and use of hemostatic agents to reduce 
blood loss intraoperatively and greater use of intravenous 
iron to manage postoperative anemia.  
CONCLUSION 
 Patient-focused blood management is increasingly being 
seen as the new standard of care.[83, 85] Patient blood 
management is an evidence-based concept as opposed to a 
behaviour-based paradigm.[92] It can result in significant 
reductions in transfusion and cost savings while improving 
patient outcomes. However, implementation requires a 
cultural shift among all levels of the health care system. If 
we fail to change the paradigm, as a 2006 editorial in 
Critical Care Medicine stated, “we do so to the profound 
detriment of patients.”[93] 
 
Fig. (4). Red blood cell units issued per 1,000 population for the State of Western Australia 2008-09 to 2013-14 (published and 
unpublished data). Printed with permission National Blood Authority (Australia). Issuances have decreased every year since the beginning of 
the Western Australia Patient Blood Management Program, despite beginning with the lowest issuance rate per 1,000 population in the 
developed world. 
8    The Open Anesthesiology Journal, 2015, Volume 9 Farmer et al. 
CONFLICTS OF INTEREST 
 No funding was received for the preparation of this 
manuscript. KT, JS, AM, GP, JH, SR and ML confirm they 
have no conflicts of interest. SF has received consulting/ 
lecture honoraria or travel support from Western Australia, 
Queensland, New South Wales and South Australia Depart-
ments of Health, Australian Red Cross Blood Service, 
Australian National Blood Authority, Australian Jurisdictional 
Blood Committee, Medical Society for Blood Management, 
Society for the Advancement of Blood Management, 
Fremantle General Practice Network, Western Australia, 
Thieme, Stuttfart German, Elesveir Science USA, Haema-
tology Society of Australia and New Zealand/ Australia and 
New Zealand Society of Blood Transfusion, Novo Nordisk, 
Vifor Pharma Ltd., Johnson & Johnson Ethicon Biosurgery. 
He is an Associate Investigator, Chief Investigator and 
Principal Investigator of 3 government sponsored research 
trials and a member of the Expert Panel for the European 
Commission Patient Blood Management Project. AH has in 
the past 5 years received honoraria and/or travel support for 
professional services related to program implementation, 
health economic analyses, outcomes research as well as 
lecturing from the following companies and legal entities: 
Amgen GmbH, Switzerland, Australian Red Cross Blood 
Service, Australia, Austrian Institute of Technology GmbH, 
Austria, CSL Behring Lda, Portugal, BBraun AG, Germany, 
CSL Behring GmbH,, Germany, Ethicon Biosurgery, USA, 
Fresenius Kabi GmbH, Germany, Hospira Ltd, United 
Kingdom, Johnson & Johnson Medical Pty Ltd, Australia, 
JW Pharmaceuticals, South Korea, National Blood 
Authority, Australia, Northern Valley Anesthesiology, USA, 
Novo Nordisk Pharmaceuticals Pty Ltd, Australia, TEM 
GmbH, Germany, United States Department of Health and 
Human Services, USA, Vifor Pharma AG, Switzerland, 
Vifor Pharma Österreich GmbH, Austria, Vifor Deutschland 
GmbH, Germany, Various International Consulting Firms, 
Various Professional Medical Societies, Various Teaching 
and University Hospitals, Western Australia Department of 
Health, Australia. 
ACKNOWLEDGEMENTS  
 The Western Australia Chief Medical Officer (CMO), Dr 
Simon Towler, during whose office the Program was 
conceived and implemented. The current CMO, Dr Gary 
Geelhoed. The PBM Medical Directors, State PBM Clinical 
Coordinator (Trudi Gallagher), PBM Clinical Nurse 
Consultants, the Western Australia Department of Health 
and all the clinicians and support staff for their commitment 
to patient blood management, the Program and patient care. 
The authors gratefully acknowledge the National Blood 
Authority (Australia) for supplying RBC, FFP, 
Cryoprecipitate and platelet issues data. There was no 
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